Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Wilms Tumor 8Rhabdoid Tumor 7Osteosarcoma 7Neuroblastoma 7Lymphoma, Non-Hodgkin 7Hepatoblastoma 7Sarcoma 6Rhabdomyosarcoma 6Neuroectodermal Tumors, Primitive, Peripheral 6Medulloblastoma 6Histiocytosis, Langerhans-Cell 6Glioma 6Ependymoma 6Central Nervous System Neoplasms 5Sarcoma, Ewing 4Multiple Myeloma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lung Neoplasms 3Colorectal Neoplasms 3Rectal Neoplasms 2Ovarian Neoplasms 2Neuroendocrine Tumors 2Nasopharyngeal Carcinoma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma, B-Cell 2Immunoglobulin Light-chain Amyloidosis 2Endometrial Neoplasms 2Desmoid Tumors 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Dexamethasone 13daratumumab 7Bortezomib 7Cyclophosphamide 6Calcium Dobesilate 5ixazomib 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4venetoclax 3belantamab mafodotin 3Specimen Handling 34-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 3pomalidomide 2isatuximab 2X-Rays 2Polymerase Chain Reaction 2Phantoms, Imaging 2Magnetic Resonance Spectroscopy 2Clinical Protocols 2Biopsy 2siltuximab 1Valganciclovir 1Tissue Banks 1Therapeutics 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Positron-Emission Tomography 1Pharmaceutical Preparations 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Immunoglobulin Light-chain Amyloidosis × Phantoms, Imaging × 1 year × Clear all
NCT04847453 2026-05-13

Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis

National Cancer Institute (NCI)

Phase 1 Active not recruiting
24 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

NCT05898646 2026-03-30

Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial

Mayo Clinic

Phase 2 Recruiting
96 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡